BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 7949832)

  • 21. Porcine follicle-stimulating hormone treatment of gilts during an altrenogest-synchronized follicular phase: effects on follicle growth, hormone secretion, ovulation, and fertilization.
    Guthrie HD; Pursel VG; Wall RJ
    J Anim Sci; 1997 Dec; 75(12):3246-54. PubMed ID: 9419999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gonadotropin-releasing hormone, estradiol, and inhibin regulation of follicle-stimulating hormone and luteinizing hormone surges: implications for follicle emergence and selection in heifers.
    Haughian JM; Ginther OJ; Diaz FJ; Wiltbank MC
    Biol Reprod; 2013 Jun; 88(6):165. PubMed ID: 23658431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of follicle-stimulating hormone secretion from gonadotroph adenomas by repetitive administration of a gonadotropin-releasing hormone antagonist.
    Daneshdoost L; Pavlou SN; Molitch ME; Gennarelli TA; Savino PJ; Sergott RC; Bosley TM; River JE; Vale WW; Snyder PJ
    J Clin Endocrinol Metab; 1990 Jul; 71(1):92-7. PubMed ID: 2115048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibin A and inhibin B responses to gonadotropin withdrawal depends on stage of follicle development.
    Welt CK; Adams JM; Sluss PM; Hall JE
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2163-9. PubMed ID: 10372726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fine tuning cycle day 3 hormonal assessment of ovarian reserve improves in vitro fertilization outcome in gonadotropin-releasing hormone antagonist cycles.
    Jurema MW; Bracero NJ; Garcia JE
    Fertil Steril; 2003 Nov; 80(5):1156-61. PubMed ID: 14607567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
    König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB
    Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The step-down principle in gonadotrophin treatment and the role of GnRH analogues.
    Fauser BC; Donderwinkel P; Schoot DC
    Baillieres Clin Obstet Gynaecol; 1993 Jun; 7(2):309-30. PubMed ID: 8358893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ovulation triggering in clomiphene citrate-stimulated cycles: human chorionic gonadotropin versus a gonadotropin releasing hormone agonist.
    Schmidt-Sarosi C; Kaplan DR; Sarosi P; Essig MN; Licciardi FL; Keltz M; Levitz M
    J Assist Reprod Genet; 1995 Mar; 12(3):167-74. PubMed ID: 8520180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent pituitary-gonadal axis suppression and extremely low anaphylactoid activity of a new gonadotropin releasing hormone (GnRH) receptor antagonist "azaline B".
    Campen CA; Lai MT; Kraft P; Kirchner T; Phillips A; Hahn DW; Rivier J
    Biochem Pharmacol; 1995 May; 49(9):1313-21. PubMed ID: 7763313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of a GnRH antagonist on follicle maturation in normal women.
    Pousias S; Messini CI; Anifandis G; Sveronis G; Georgoulias P; Daponte A; Messinis IE; Dafopoulos K
    Reprod Biomed Online; 2019 Jul; 39(1):84-92. PubMed ID: 31129014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effects of two different delivery systems on gonadotropin-releasing hormone (GnRH) antagonist-induced suppression of gonadotropins and testosterone in man.
    Salameh W; Bhasin S; Steiner BS; McAdams LA; Peterson M; Rivier JE; Vale WW; Swerdloff RS
    J Androl; 1994; 15(1):22-8. PubMed ID: 8188535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin.
    Fraser HM; Nestor JJ; Vickery BH
    Endocrinology; 1987 Aug; 121(2):612-8. PubMed ID: 3109885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ovulatory follicle dysfunction in lactating dairy cows after treatment with Folltropin-V at the onset of luteolysis.
    Giordano JO; Edwards JL; Di Croce FA; Roper D; Rohrbach NR; Saxton AM; Schuenemann GM; Prado TM; Schrick FN
    Theriogenology; 2013 May; 79(8):1210-7. PubMed ID: 23534994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Even after priming with ovarian steroids or pulsatile gonadotropin-releasing hormone administration, naltrexone is unable to induce ovulation in women with functional hypothalamic amenorrhea.
    Couzinet B; Young J; Brailly S; Chanson P; Schaison G
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2102-7. PubMed ID: 7608262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of gonadotrophin surge-attenuating factor during the luteal phase in superovulated women.
    Messinis IE; MacTavish A; Templeton AA
    J Reprod Fertil; 1993 Jan; 97(1):271-5. PubMed ID: 8464020
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.